JP5410985B2 - 液体抗狂犬病抗体製剤 - Google Patents

液体抗狂犬病抗体製剤 Download PDF

Info

Publication number
JP5410985B2
JP5410985B2 JP2009539730A JP2009539730A JP5410985B2 JP 5410985 B2 JP5410985 B2 JP 5410985B2 JP 2009539730 A JP2009539730 A JP 2009539730A JP 2009539730 A JP2009539730 A JP 2009539730A JP 5410985 B2 JP5410985 B2 JP 5410985B2
Authority
JP
Japan
Prior art keywords
antibody
formulation
rabies virus
months
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009539730A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010511665A (ja
JP2010511665A5 (https=
Inventor
ベルトールド ヘンドリク ベッカー アレクザンダー
エフベルト マリッセン ウィレム
Original Assignee
クルセル ホランド ベー ヴェー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クルセル ホランド ベー ヴェー filed Critical クルセル ホランド ベー ヴェー
Publication of JP2010511665A publication Critical patent/JP2010511665A/ja
Publication of JP2010511665A5 publication Critical patent/JP2010511665A5/ja
Application granted granted Critical
Publication of JP5410985B2 publication Critical patent/JP5410985B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2009539730A 2006-12-05 2007-12-04 液体抗狂犬病抗体製剤 Expired - Fee Related JP5410985B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87289206P 2006-12-05 2006-12-05
US60/872,892 2006-12-05
EP06125400.9 2006-12-05
EP06125400 2006-12-05
PCT/EP2007/063244 WO2008068246A1 (en) 2006-12-05 2007-12-04 Liquid anti-rabies antibody formulations

Publications (3)

Publication Number Publication Date
JP2010511665A JP2010511665A (ja) 2010-04-15
JP2010511665A5 JP2010511665A5 (https=) 2011-01-20
JP5410985B2 true JP5410985B2 (ja) 2014-02-05

Family

ID=39092188

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009539730A Expired - Fee Related JP5410985B2 (ja) 2006-12-05 2007-12-04 液体抗狂犬病抗体製剤

Country Status (13)

Country Link
US (1) US7959922B2 (https=)
EP (1) EP2088997B1 (https=)
JP (1) JP5410985B2 (https=)
KR (1) KR101522036B1 (https=)
CN (1) CN101557799B (https=)
AU (1) AU2007328960B2 (https=)
CA (1) CA2668947C (https=)
CU (1) CU23795A3 (https=)
EA (1) EA017549B1 (https=)
IL (1) IL199004A (https=)
MX (1) MX2009005414A (https=)
WO (1) WO2008068246A1 (https=)
ZA (1) ZA200902772B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ543635A (en) 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
CN1961002B (zh) * 2004-05-27 2011-05-18 克鲁塞尔荷兰公司 能中和狂犬病病毒的结合分子及其应用
WO2007141274A2 (en) * 2006-06-06 2007-12-13 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
CN101557799B (zh) 2006-12-05 2012-08-22 克鲁塞尔荷兰公司 液体抗狂犬病抗体制剂
JP2010085126A (ja) * 2008-09-29 2010-04-15 Adtec Kk 狂犬病ウイルス中和抗体価判定具および狂犬病ウイルス中和抗体価の測定方法
WO2011028961A2 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Anti-botulism antibody coformulations
SG10201604104PA (en) 2011-10-25 2016-07-28 Prothena Therapeutics Ltd Antibody formulations and methods
AU2013230490B2 (en) 2012-03-07 2017-04-13 Eli Lilly And Company IL-17 antibody formulation
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP7159642B2 (ja) * 2018-06-26 2022-10-25 東ソー株式会社 カラムの抗体に対する保持力の測定方法
KR102885113B1 (ko) 2018-10-18 2025-11-13 머크 샤프 앤드 돔 엘엘씨 항-rsv 항체의 제제 및 그의 사용 방법
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
JP2023529010A (ja) 2020-06-12 2023-07-06 ナンチン リーズ バイオラブス カンパニー，リミティド Ｔｎｆｒ２に結合する抗体およびその用途
CN114748618B (zh) * 2022-04-02 2024-07-19 重庆智翔金泰生物制药股份有限公司 包含针对狂犬病病毒g蛋白的双特异性抗体的药物制剂及其制备方法
CN117771365B (zh) * 2023-12-07 2025-07-04 兰州生物制品研究所有限责任公司 一种抗狂犬病病毒组合单克隆抗体制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0402029B1 (en) 1989-06-08 1994-01-12 The Wistar Institute Monoclonal antibodies for post exposure treatment of rabies
DE4006630A1 (de) 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
EP0934526B1 (en) 1996-10-08 2003-01-08 U-BISys B.V. Methods and means for selecting peptides and proteins having specific affinity for a target
US20040013672A1 (en) * 2000-05-16 2004-01-22 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
NZ531291A (en) 2001-08-21 2006-02-24 Univ Jefferson Recombinant anti rabies antibodies MAb JB.1 and Mab 57 and compositions and methods for making and using the same
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
CA2537371A1 (en) 2003-09-04 2005-03-17 Crucell Holland B.V. Antigenic peptides of rabies virus and uses thereof
US7803914B2 (en) * 2003-10-09 2010-09-28 Chugai Seiyaku Kabushiki Kaisha Methods for stabilizing protein solutions
WO2005035574A1 (ja) * 2003-10-09 2005-04-21 Chugai Seiyaku Kabushiki Kaisha IgM高濃度安定化溶液
WO2005063291A1 (ja) * 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha 抗体を含有する安定な水性医薬製剤
CN1961002B (zh) * 2004-05-27 2011-05-18 克鲁塞尔荷兰公司 能中和狂犬病病毒的结合分子及其应用
WO2006112838A1 (en) * 2005-04-18 2006-10-26 Xtl Biopharmaceuticals Ltd. Stabilized anti-hepatitis b (hbv) antibody formulations
CN101557799B (zh) 2006-12-05 2012-08-22 克鲁塞尔荷兰公司 液体抗狂犬病抗体制剂

Also Published As

Publication number Publication date
WO2008068246A1 (en) 2008-06-12
EP2088997A1 (en) 2009-08-19
CN101557799B (zh) 2012-08-22
IL199004A (en) 2015-10-29
CN101557799A (zh) 2009-10-14
EA017549B1 (ru) 2013-01-30
KR101522036B1 (ko) 2015-05-20
EA200970533A1 (ru) 2009-10-30
IL199004A0 (en) 2010-02-17
US7959922B2 (en) 2011-06-14
US20100034829A1 (en) 2010-02-11
CA2668947A1 (en) 2008-06-12
AU2007328960B2 (en) 2013-01-17
MX2009005414A (es) 2009-06-01
JP2010511665A (ja) 2010-04-15
ZA200902772B (en) 2012-09-26
CA2668947C (en) 2017-02-07
KR20090089881A (ko) 2009-08-24
EP2088997B1 (en) 2016-08-24
AU2007328960A1 (en) 2008-06-12
CU23795A3 (es) 2012-03-15

Similar Documents

Publication Publication Date Title
JP5410985B2 (ja) 液体抗狂犬病抗体製剤
CN111315411B (zh) 高浓度抗c5抗体制剂
RU2644214C2 (ru) СТАБИЛЬНЫЕ ПРЕПАРАТЫ СВЯЗЫВАЮЩЕГО СРЕДСТВА НА ОСНОВЕ IgG4
KR20160068946A (ko) 안정한 수성 항체 제제
TWI764097B (zh) 包含抗ｃｄ４７抗體的製劑及其製備方法和用途
KR102885113B1 (ko) 항-rsv 항체의 제제 및 그의 사용 방법
JP2020534255A (ja) 治療用タンパク質の凍結乾燥医薬配合物のためのプロセス
KR20220137159A (ko) 항체 제형
US20230066762A1 (en) Immunogenic composition
AU2020325569B2 (en) Process for preparing a composition comprising a protein D polypeptide
ES2602275T3 (es) Formulaciones líquidas de anticuerpo anti-rabia
CA3115708C (en) Formulations of anti-rsv antibodies and methods of use thereof
RU2807524C2 (ru) Составы антител к rsv и способы их применения
RU2847524C2 (ru) Высококонцентрированные составы антител к c5
CN121490076A (zh) 一种稳定的抗人masp2单克隆抗体制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130814

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131029

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131107

R150 Certificate of patent or registration of utility model

Ref document number: 5410985

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees